The frequency and associated factors of infusion-related reactions to rituximab for patients with rheumatoid arthritis

Objectives: Rituximab is an effective biological agent for treating patients with rheumatoid arthritis (RA). Rheumatologists can avoid rituximab therapy because of infusion-related reactions (IRR). There is a lack of data about rituximab-related IRR, especially in rituximab-naïve patients with RA; therefore, we aimed to determine the frequency and associated factors of rituximab-related IRR in these patients. Methods: Baseline demographic, laboratory, and treatment data were noted. One course of rituximab was used in two infusions to 95 rituximab-naïve patients with RA. Standardized premedication was administered before infusions. Rates, severity, and management of IRR were recorded. Efficacy and infections were also noted if there were. Results: Ninety-four of 95 patients completed the rituximab course successfully. We observed a total of 23 IRRs in 20 patients. The frequency of IRR was 12.1%, and serious IRR was 0.52%. Grade 1-2-3 IRRs had a rate of 52.2%, 30.4%, and 17.4%, respectively; grade 4 or 5 IRR wasn’t detected. Age <60 years, anti-CCP <200U/ml and absence of biologic agent use before rituximab was significantly higher in patients with IRR than without IRR (p=0.01, p=0.002, p=0.01 respectively). We found out that if only the disease age is above 60 months, it is protective against IRR as per the results of multivariate model analysis. Conclusion: Results supported that rituximab is a safe biological agent option for patients with RA at secondary central hospitals. Identified risk factors of IRR need to be corroborated in larger studies for safer rituximab therapy.

Keywords:

Rituximab, Infusion-Related Reactions, Rheumatoid Arthritis Risk Factors,

PDF

___

Grillo-López AJ, White CA, Dallaire BK, Varns CL, Shen CD, Wei A, et al. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol. 2000;1(1):1-9. https://doi.org/10.2174/1389201003379059.
Engel P, Gómez-Puerta JA, Ramos-Casals M, Lozano F, Bosch X. Therapeutic targeting of B cells for rheu-matic autoimmune diseases. Pharmacol Rev. 2011;63 (1):127-156. https://doi.org/10.1124/pr.109.002006.
Cohen SB, Emery P, Greenwald MW, Dougados M, Furie FA, Genovese MC, et al. Rituximab for rheuma-toid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum. 2006;54(9):2793-2806. https://doi.org/ 10.1002/art.22025.
Food and Drug Administration. [webpage on the Internet]. Questions and answers on rituximab (added 12/19/2006). Available from: https://wayback.archiveit.org/7993/20170722191606/https://www.fda.gov/Drugs/DrugSafety/Postmarket Drug Safety Information for Patients and Providers/ucm109107.htm. Accessed August 9, 2017.
Schioppo T, Ingegnoli F. Current perspective on rituximab in rheumatic diseases. Drug Des Devel Ther. 2017;11:2891-2904. https://doi.org/ 10.2147/DDDT.S139248.
Pichler WJ. Adverse side-effects to biological agents. Allergy. 2006;61(8):912-920. https://doi.org/ 10.1111/j.1398-9995.2006.01058.x.
Vogel WH. Infusion reactions: diagnosis, assessment, and management. Clin J Oncol Nurs. 2010;14(2): E10-21. https://doi.org/ 10.1188/10.CJON.E10-E21.
van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann R, Furst DE, et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol. 2010;37(3):558-567. https://doi.org/ 10.3899/jrheum.090856.
Aletaha D, Neogi T, Silman AJ, Funovtis J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism col-laborative initiative. Arthritis Rheum. 2010;62(9):2569-2581. https://doi.org/10.1002/art.27584.
Doesseger L, Banholzer ML. Clinical development methodology for infusion-related reactions with mo-noclonal antibodies. 2015:17;4(7):e39. https://doi.org/ 10.1038/cti.2015.14.
National Cancer Institute. Common Terminology Criteria for Adverse Events v5.0. (CTCAE) Publish date November 27, 2017. https://ctep.cancer.gov/protocoldevelop-ment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.
van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum. 1998;41(10):1845-1850. https://doi.org/10.1002/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K.
Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dörner T, et al. Updated consensus sta-tement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(6):909-920. https://doi.org/ 10.1136/ard.2010.144998.
Pritchard CH, Greenwald MW, Kremer JM, Gaylis NB, Rigby W, Zlotnick S, et al. Safety of infusing ri-tuximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study. BMC Musculoskelet Disord. 2014;15:177. https://doi.org/10.1186/1471-2474-15-177.
Salmon JH, Perotin JM, Morel J, Dramé M, Cantagrel A, Ziegler LE. Serious infusion-related reaction after rituximab, abatacept, and tocilizumab in rheumatoid arthritis: prospective registry data. Rheumatology (Oxford). 2018;57(1):134-139. https://doi.org/10.1093/rheumatology/kex403.
Atzeni F, Turiel M, Capsoni F, Doria A, Meroni P, Sarzi-Puttini S. Autoimmunity and anti-TNF-alpha agents. Ann N Y Acad Sci. 2005;1051:559-569. https://doi.org/10.1196/annals.1361.100.
Conti F, Ceccarelli F, Perricone C, Alessandri C, Conti V, Massaro L, et al. Rituximab infusion-related adver-se event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis. Rheumatology (Oxford). 2011;50(6):1148-1152. https://doi.org/10.1093/rheumatology/keq436.
Rovin BH, Furie B, Latinis K, Looney RJ, Fervenza FC, Guerrero JS, et al. LUNAR Investigator Group. Effi-cacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis As-sessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215-1226. https://doi.org/ 10.1002/art.34359.
D’Arena G, Simeon V, Laurenti, Cimminiello M, Innocenti I, Gilio M, et al. Adverse drug reactions after intravenous rituximab infusion is more common in hematologic malignancies than in autoimmune di-sorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients. Leuk Lymphoma. 2017;58(11):2633-2641. https://doi.org/ 10.1080/10428194.2017.1306648.
McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of the patients respond to a four-dose treatment program. J Clin Oncol. 1998;16(8):2825-33. https://doi.org/ 10.1200/JCO.1998.16.8.2825.
Brown BA, Torabi M. Incidence of infusion-associated reactions with rituximab for treating multiple scle-rosis: a retrospective analysis of patients treated at a US centre. Drug Saf. 2011;34(2):117-123. https://doi.org/ 10.2165/11585960-000000000-00000.
Hauser SL, Waubant E, Arnold DL, Wollmer T, Antel J, Fox RJ, et al. B-Cell depletion with rituximab in re-lapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676-88. https://doi.org/10.1056/NEJMoa0706383.
Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody the-rapy. Oncologist. 2008;13(6):725-732. https://doi.org/10.1634/theoncologist.2008-0012.
Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005;31(6):456-73. https://doi.org/10.1016/j.ctrv.2005.05.007
Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with anti-CD20 monoc-lonal antibody (rituximab, IDEC-C2B8). Blood 1999;94:2217-2224.
Frasca D, Diaz A, Romero M, Landin AM, Blomberg BB. Age effects on B cells and humoral immunity in humans. Ageing Res Rev. 2011;10(3):330-335. https://doi.org/10.1016/j.arr.2010.08.004.